Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C24H29NO3 · HCl
Número CAS:
Peso molecular:
415.95
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlegrade
pharmaceutical primary standard
agency
USP
API family
donepezil
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
Cl.N2(CCC(CC2)CC3Cc4c(cc(c(c4)OC)OC)C3=O)Cc1ccccc1
InChI
1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H
InChI key
XWAIAVWHZJNZQQ-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Donepezil hydrochloride
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Eye Irrit. 2
Clase de almacenamiento
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Yusuke Yatabe et al.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 13(2), 88-93 (2013-08-06)
With the recent approval of several new drugs, pharmacological management of Alzheimer's disease has become more complicated in Japan. The efficacy and safety of increasing the dose of donepezil to 10 mg daily were assessed in an open-label study of patients
Marwan Sabbagh et al.
BMC geriatrics, 13, 56-56 (2013-06-08)
Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated
Manabu Ikeda et al.
Dementia and geriatric cognitive disorders, 36(3-4), 229-241 (2013-08-21)
To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized